Fosun Pharma trades at 18.08 times earnings: Fosun Pharma stock yields 0.02 percent

Published on 10/20/2026 at 19:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Henlius revenue rose 27.30 percent to CNY 3.59 billion in first half 2026. Fosun Pharma stock costs EUR 1.95 on October 20, 2026.

Valuation and growth figures

Fosun Pharma trades at 18.08 times earnings and carries a 0.02 percent dividend yield as of October 20, 2026.
Henlius revenue rose 27.30 percent to CNY 3.59 billion in the first half of 2026.
Fosun Pharma stock costs EUR 1.95 at Lang & Schwarz on October 20, 2026 at 7:10 p.m. CEST.
Fosun Pharma is scheduled to report third-quarter results on October 27, 2026.

Fosun Pharma, CNE100001M79, Illustration mit AI erstellt.

Fosun Pharma (ISIN CNE100001M79) trades at 18.08 times earnings, while its trailing dividend yield stands at 0.02 percent as of October 20, 2026. BioSpectrum Asia reported on October 18, 2026 that Henlius revenue increased 27.30 percent year over year to CNY 3.59 billion in the first half of 2026. At Lang & Schwarz on October 20, 2026 at 7:10 p.m. CEST, Fosun Pharma stock was trading at EUR 1.95.

Henlius adds a growth counterweight

The Henlius figure gives Fosun Pharma a quantified growth driver beyond the group's consolidated revenue. Innovative drugs represented 33.35 percent of pharmaceutical revenue in the first half of 2026, while Henlius reported net profit of CNY 430.40 million, up 10.30 percent year over year, according to BioSpectrum Asia.

Shanghai quote stays inside range

The Shanghai-listed shares last stood at CNY 23.14 on October 20, 2026 at 3:00 p.m. China Standard Time, with 11,948,060 shares traded. The 52-week range ran from CNY 20.85 to CNY 29.68, placing the quote CNY 6.54 below its high and CNY 2.29 above its low. The company's market capitalization was CNY 61.8 billion on the same date.

Valuation meets a fixed date

Fosun Pharma's next scheduled reporting date is October 27, 2026, for third-quarter results covering the nine months ended September 30, 2026, according to Hong Kong Exchanges and Clearing. The date gives the market a near-term checkpoint for whether the first-half mix of innovative medicines and international expansion continued into the second half.

What does the growth mix mean?

Henlius' 27.30 percent revenue increase compares with its 10.30 percent net-profit growth, so revenue expansion has not translated into an equal earnings increase. Fosun Pharma's investor-relations page describes a portfolio spanning pharmaceutical manufacturing, medical devices, diagnostics and healthcare services, with innovation and internationalization as strategic priorities.

Fosun Pharma stock at Lang & Schwarz

The euro quotation was EUR 1.95 at Lang & Schwarz on October 20, 2026 at 7:10 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Fosun Pharma stock.